Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a nationwide cohort study

被引：0
|
作者：
Funck, K. L. [1 ]
Bjerg, L. [1 ]
Isaksen, A. A. [1 ]
Sandbaek, A. [1 ]
Grove, E. L. [2 ]
机构：
[1] Aarhus Univ Hosp, Steno Diabet Ctr Aarhus, Aarhus, Denmark
[2] Aarhus Univ Hosp, Dept Cardiol, Aarhus N, Denmark
来源：
DIABETOLOGIA | 2022年 / 65卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
336
引用
收藏
页码：S176 / S176
页数：1
相关论文
共 50 条
  • [31] Initial glucose-lowering therapy and cardiovascular outcomes in type 2 diabetes
    Misnikova, I. V.
    Dreval, A. V.
    Kovaleva, Y. A.
    DIABETOLOGIA, 2012, 55 : S326 - S326
  • [32] Glucose-Lowering Therapy in Patients With Postpancreatitis Diabetes Mellitus: A Nationwide Population-Based Cohort Study
    Viggers, Rikke
    Jensen, Morten Hasselstrom
    Laursen, Henrik Vitus Bering
    Drewes, Asbjorn Mohr
    Vestergaard, Peter
    Olesen, Soren Schou
    DIABETES CARE, 2021, 44 (09) : 2045 - 2052
  • [33] Glucose-Lowering Therapy in Patients With Postpancreatitis Diabetes Mellitus: A Nationwide Population-Based Cohort Study
    Viggers, R.
    Jensen, M. Hasselstrom
    Laursen, H. Vitus Bering
    Drewes, A. M.
    Vestergaard, P.
    Olesen, S. S.
    PANCREAS, 2021, 50 (07) : 1106 - 1107
  • [34] Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
    Rozalina G. McCoy
    Jeph Herrin
    Kavya Sindhu Swarna
    Yihong Deng
    David M. Kent
    Joseph S. Ross
    Guillermo E. Umpierrez
    Rodolfo J. Galindo
    William H. Crown
    Bijan J. Borah
    Victor M. Montori
    Juan P. Brito
    Joshua J. Neumiller
    Mindy M. Mickelson
    Eric C. Polley
    Nature Cardiovascular Research, 2024, 3 : 431 - 440
  • [35] Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
    Mccoy, Rozalina G.
    Herrin, Jeph
    Swarna, Kavya Sindhu
    Deng, Yihong
    Kent, David M.
    Ross, Joseph S.
    Umpierrez, Guillermo E.
    Galindo, Rodolfo J.
    Crown, William H.
    Borah, Bijan J.
    Montori, Victor M.
    Brito, Juan P.
    Neumiller, Joshua J.
    Mickelson, Mindy M.
    Polley, Eric C.
    NATURE CARDIOVASCULAR RESEARCH, 2024, 3 (04): : 431 - 440
  • [36] Cardiovascular outcome trials of glucose-lowering drugs in type 2 diabetes: 10 frequently asked questions
    George, Jyothis T.
    PRACTICAL DIABETES, 2015, 32 (08) : 301 - 304
  • [37] Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes
    Cattadori, Gaia
    Pantanetti, Paola
    Ambrosio, Giuseppe
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 157
  • [38] Glucose-lowering treatment influences risk of death in patients with diabetes: a nationwide study
    Schramm, T. K.
    Gislason, G.
    Rasmussen, S.
    Rasmussen, J. N.
    Folke, F.
    Hansen, M. L.
    Fosbol, E. L.
    Kober, L.
    Torp-Pedersen, C.
    Vaag, A.
    EUROPEAN HEART JOURNAL, 2008, 29 : 140 - 140
  • [39] Concomitant use of benzodiazepines and oral glucose-lowering drugs in patients with type-2 diabetes
    Fornero, Agostina
    Bertoldo, Pamela
    Dumont, Nilda
    FARMACEUTICOS COMUNITARIOS, 2018, 10 (01): : 41 - 46
  • [40] Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes
    Chen, Wei-Han
    Li, Yujia
    Yang, Lanting
    Allen, John M.
    Shao, Hui
    Donahoo, William T.
    Billelo, Lori
    Hu, Xia
    Shenkman, Elizabeth A.
    Bian, Jiang
    Smith, Steven M.
    Guo, Jingchuan
    PLOS ONE, 2024, 19 (01):
12345